Mark Didmon

Mark Didmon

Partner - Patent Attorney

Mark is a leading patent specialist in the life sciences sector, with extensive experience in devising effective global patent strategies and helping clients achieve their commercial objectives.

Following his degree and PhD, Mark completed a two-year post-doctoral fellowship in mammalian molecular biology at the Imperial Cancer Research Fund (now Cancer Research UK) in Dundee. His studies included research at AstraZeneca in the UK and Novartis in Austria, and his work has been published in peer-reviewed journals including the Journal of Biological Chemistry and Nature.  

Mark is an experienced advocate at the European Patent Office, having handled around 100 cases at the EPO Opposition Divisions and Boards of Appeal (including recent high-profile opposition cases involving CRISPR gene-editing technology).

In 2014, Mark qualified as a patent attorney litigator and was awarded a Higher Courts Litigation Certificate. His experience includes High Court and Court of Appeal successes in Stretchline Intellectual Properties Limited v. H&M Hennes & Mauritz Limited.

Mark is a Unified Patent Court representative, and acted before the Munich Central Division in two of the first UPC revocation actions, in Astellas v. Healios. The cases were filed on the first day of the UPC’s operation in 2023, and were coordinated with parallel EPO opposition proceedings.

Mark joined Potter Clarkson in 2003, became a partner in 2011 and works across the firm’s European offices. He is heavily involved with clients across the Nordic region, having played a leading role in establishing the firm’s permanent presence in Denmark and Sweden.



Antibody technology, cell biology, personalised medicine, genetic engineering, industrial enzymes and biochemistry 


Mark studied microbiology and virology at the University of Warwick and obtained a PhD in molecular cell biology at the same university.


BSc (Hons), PhD, UK and European Patent Attorney, Patent Attorney Litigator

Awards & Recognition

In 2005, Mark was awarded the Moss Prize for obtaining the highest overall mark in the foundation level patent examination papers.   

Mark has been listed in the Legal 500 as “notable for expertise in the biotechnology sector” and in 2017-2024 was listed as an IP Star by Managing Intellectual Property.